Journal
CELL CHEMICAL BIOLOGY
Volume 25, Issue 9, Pages 1117-+Publisher
CELL PRESS
DOI: 10.1016/j.chembiol.2018.06.004
Keywords
-
Categories
Funding
- Medical Research Council UK [MC_UU_12016/5]
- Division of Signal Transduction Therapy (DSTT) (Boehringer-Ingelheim)
- Division of Signal Transduction Therapy (DSTT) (GlaxoSmithKline)
- Division of Signal Transduction Therapy (DSTT) (Merck KGaA)
- MRC [MC_UU_12016/5] Funding Source: UKRI
Ask authors/readers for more resources
Due to their role in many diseases, enzymes of the ubiquitin system have recently become interesting drug targets. Despite efforts, primary screenings of compound libraries targeting E2 enzymes and E3 ligases have been strongly limited by the lack of robust and fast high-throughput assays. Here we report a label-free high-throughput screening assay for ubiquitin E2 conjugating enzymes and E3 ligases based on MALDI-TOF mass spectrometry. The MALDI-TOF E2/E3 assay allows testing E2 enzymes and E3 ligases for their ubiquitin transfer activity, identifying E2/E3 active pairs, inhibitor potency and specificity and screening compound libraries in vitro without chemical or fluorescent probes. We demonstrate that the MALDI-TOF E2/E3 assay is a universal tool for drug discovery screening in the ubiquitin pathway as it is suitable for working with all E3 ligase families and requires a reduced amount of reagents, compared with standard biochemical assays.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available